Comparison of the 2013 ACC/AHA guidelines, 2016 USPSTF recommendations and ATP III guidelines for the management of dyslipidaemia in a Macau SAR cohort.
Objective: Atherosclerotic cardiovascular disease is a major cause of death, and there are many published guidelines for the management of blood cholesterol. This study compared differences in the implementation of the National Cholesterol Education Program Adult Treatment Panel III (ATP III) guidelines, the 2013 American College of Cardiology and the American Heart Association (ACC/AHA) guidelines and the U.S. Preventive Services Task Force (USPSTF) 2016 recommendations for the management of dyslipidaemia in the Macau SAR population. Methods: In total, 896 patients fulfilled the inclusion criteria. Risk estimation was based on the patient lipid profiles and risk factors prior to initiating statins. The proportions of the study population who qualified for statin treatment under the above three guidelines were determined. Results: The comparison of the ATP III guidelines with the 2013 ACC/AHA guidelines showed that 154 (17.2%) additional patients were eligible for statins. The comparison of the USPSTF 2016 recommendations with the 2013 ACC/AHA guidelines revealed that the former resulted in 150 (16.7%) additional patients who were eligible for statins. When compared with the 2013 ACC/AHA guidelines and the USPSTF 2016 recommendations, the ATP III guidelines are more likely to recommend treatment for younger individuals, females, and those with higher total cholesterol and LDL-C. Conclusion: Application of various guidelines led to different populations who were eligible for statins. The 2013 ACC/AHA guidelines for lipid-lowering medications resulted in a significant increase in the population eligible for statins